Sanchez-Holgado Maria, Sampedro Mercedes, Zozaya Carlos, Permuy Romero Celia, Alvarez-Garcia Patricia, La Banda-Montalvo Leticia, Nieto Clara, Pellicer Adelina
Department of Neonatology. La Paz University Hospital, Madrid, Spain.
J Perinatol. 2025 Feb;45(2):224-228. doi: 10.1038/s41372-024-02200-1. Epub 2024 Dec 16.
To evaluate the therapeutic dose and safety of bemiparin in neonatal thrombosis treatment.
A retrospective review was conducted on infants treated with bemiparin between 2018 and 2023 at a tertiary hospital.
72 neonates with a mean gestational age of 37 weeks were included. Twenty were preterm, with a median gestational age of 33.5 weeks and a median birth weight of 1847.5 grams. The mean (SD) initial and therapeutic bemiparin doses were 170.5 (31) and 200 (37.2) IU/kg/day, respectively. Only 32% of patients reached the therapeutic target range (TTR) with the initial dose. Preterm infants required higher doses to reach TTR (215 vs 194.7 IU/kg/day, p = 0.05). Adverse events were minimal (1.4%) and unrelated to the starting dose or prematurity.
Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration.
评估贝米肝素治疗新生儿血栓形成的治疗剂量和安全性。
对2018年至2023年在一家三级医院接受贝米肝素治疗的婴儿进行回顾性研究。
纳入72例平均胎龄为37周的新生儿。其中20例为早产儿，中位胎龄为33.5周，中位出生体重为1847.5克。贝米肝素的平均（标准差）初始剂量和治疗剂量分别为170.5（31）和200（37.2）IU/kg/天。只有32%的患者初始剂量达到治疗目标范围（TTR）。早产儿达到TTR需要更高的剂量（215比194.7 IU/kg/天，p = 0.05）。不良事件极少（1.4%），且与起始剂量或早产无关。
贝米肝素似乎是新生儿抗凝治疗的一种潜在选择；然而，初始剂量很少能达到目标抗Xa水平，大多数患者需要增加剂量。
